Andrew brings more than 20 years of global leadership in drug development, regulatory strategy, and commercialization across the United States, Europe, and international markets. He was previously the CEO of bluebird bio, recently renamed Genetix Biotherapeutics, where he led the company’s transformation into a global commercial-stage gene therapy enterprise, successfully secured multiple regulatory approvals across […]
Nazira is a physician and senior commercial executive with more than 25 years of experience across global pharmaceutical, biotechnology, and emerging techbio companies. She brings deep expertise in cardiometabolic disease, including MASH, and has led multiple global product launches. Nazira previously held multiple senior leadership roles at Sanofi, where she led global franchises and regional […]
Jason brings more than 20 years of leadership experience in early- and late-stage clinical development across leading biopharmaceutical companies. Most recently, he served as Chief Medical Officer at Q32 Bio, where he oversaw clinical strategy and development. Previously, Jason held multiple leadership roles at Intercept Pharmaceuticals, including Head of the Global MASH Program, which led […]
Pascaline brings more than 20 years of leadership experience spanning biotechnology, government, academia, and non-profit organizations. Her background combines scientific training with deep expertise in public policy, legislative affairs, advocacy, and strategic communications across the United States and Europe. She has developed particular expertise in MASH and in stakeholder engagement at the intersection of science, […]
Susan is an experienced legal executive with more than 25 years of expertise in international collaborations, corporate governance, licensing, and commercial transactions, particularly in the life sciences sector. She previously served as General Counsel of Vivet Therapeutics from 2017 to 2025 and of Stallergenes from 2014 to 2017. Susan also previously served as General Counsel […]
Pamela brings more than 25 years of leadership experience in human resources, organizational transformation, and business operations across the biopharmaceutical and healthcare sectors. She joins Inventiva from Sage Therapeutics, where she served as Senior Vice President, Chief People & Experience Officer and played a key role in supporting the company’s growth, talent strategy, and organizational […]
Axel-Sven brings more than 30 years of experience in finance, capital markets, M&A, and corporate leadership across the life sciences sector. Most recently, he served as Chief Financial Officer of CureVac N.V., where he played a key role in the company’s transformation and in its acquisition by BioNTech. Previously, he served as CFO of Cardior […]
Martine brings over 30 years of combined experience in R&D and global regulatory strategy. Most recently, she served as Senior Vice President, Head of Regulatory Affairs at Ipsen, where she successfully led the team that secured regulatory approvals for two liver disease therapies, including a dual PPARα/δ agonist for the treatment of primary biliary cholangitis. […]
